News headlines about Catabasis Pharmaceuticals (NASDAQ:CATB) have trended somewhat positive on Tuesday, Accern reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Catabasis Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.3384121051808 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of Catabasis Pharmaceuticals (CATB) traded down $0.07 during trading hours on Tuesday, reaching $1.68. The company had a trading volume of 167,300 shares, compared to its average volume of 1,030,736. Catabasis Pharmaceuticals has a 1-year low of $1.08 and a 1-year high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.02. The company had revenue of $0.25 million for the quarter. analysts forecast that Catabasis Pharmaceuticals will post -1.42 EPS for the current fiscal year.

A number of equities analysts have recently weighed in on CATB shares. Cowen reiterated a “market perform” rating and set a $2.00 target price on shares of Catabasis Pharmaceuticals in a research note on Friday, October 6th. Zacks Investment Research upgraded Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research note on Thursday, November 16th. Oppenheimer lowered their target price on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 15th. HC Wainwright increased their target price on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Monday, August 14th. Finally, Citigroup upgraded Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 target price on the stock in a research note on Monday, November 20th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Catabasis Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $4.82.

TRADEMARK VIOLATION WARNING: “Catabasis Pharmaceuticals (CATB) Receiving Somewhat Favorable News Coverage, Study Finds” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Insider Buying and Selling by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Stock Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.